Meningitis Vaccine: Precautionary Recall

This article originally appeared here.
Share this content:
Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by <I>Neisseria meningitidis</i>.
Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis.

GlaxoSmithKline has initiated a recall of Menveo (meningococcal [Groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) for intramuscular injection.1

Specifically, the recall is for NDC# 46028-208-01; Lot#  M16095 with expiration date of March 2018. The recalled product is supplied with the accompanying MenCYW-135 liquid conjugate vaccine component (NDC# 46028-218-11).

This recall is considered precautionary as the batch associated with the recall was subject to a "mechanical intervention executed during the aseptic filling operations, which is not supported by validation data." 

Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. It is approved for use in persons 2 months through 55 years of age.

Follow @ClinicalPainAdv

Reference

  1. Recall of MENVEO [Meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine] solution for intramuscular injection [press release]. Washington DC: FDA; July 18, 2017.
You must be a registered member of Clinical Pain Advisor to post a comment.